Bethany Dudek Joins Arcutis as Vice President of Quality
August 04 2020 - 9:00AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Bethany Dudek has joined the company as Vice President of
Quality. As the Arcutis Quality head, Ms. Dudek will be responsible
for all aspects of quality as the Company prepares for the
potential future commercialization of its product candidates.
“Bethany brings more than 25 years of diverse
experience in various technical operations and quality positions,
and has demonstrated her leadership and effectiveness in
commercializing new medicines and ensuring product quality within
multiple organizations,” said Patricia Turney, Senior Vice
President of Operations. “At Arcutis, we are embarking on a bold
strategy to become the preeminent innovation-driven medical
dermatology company. As we prepare for potential commercialization,
Bethany’s extensive biopharmaceutical quality knowledge and
compliance-driven mindset will be invaluable, and we look forward
to her contributions to our future development.”
Prior to joining Arcutis, Ms. Dudek was at Kite
Pharma, where she held roles of increasing responsibility,
culminating in the role of Executive Director of Quality Europe,
where she was responsible for all aspects of quality to
support supply and distribution of cell therapy products in EU and
non-EU countries and was responsible for quality assurance and
quality control for new clinical and commercial manufacturing sites
for cell therapy products. Prior to Kite, Ms. Dudek was Senior
Director of Quality Assurance at Kythera Biopharmaceuticals, where
she was responsible for oversight of the Quality Assurance
organization as it transitioned from development to commercial
operations for KYBELLA®. Earlier in her career she was Technical
Operations Head, Pediatrics and Specialty Franchise at Novartis
Vaccines and Diagnostics. Previously, Ms. Dudek held various roles
of increasing responsibility at Amgen, Inc., culminating in the
role of Director, Global Operations Leader. Ms. Dudek received her
B.A. in Biology Ithaca College.
About Arcutis - Bioscience, applied to the
skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology. The company is
leveraging recent advances in immunology and inflammation to
develop differentiated therapies against biologically validated
targets to solve persistent treatment challenges in serious
diseases of the skin. Arcutis’ robust pipeline includes four novel
drug candidates currently in development for a range of
inflammatory dermatological conditions. The company’s lead product
candidate, topical roflumilast, has the potential to revitalize the
standard of care for plaque psoriasis, atopic dermatitis, scalp
psoriasis, and seborrheic dermatitis. For more information,
visit https://www.arcutis.com or follow the company on LinkedIn and
Twitter.
Investors and Media:Heather Rowe ArmstrongVice
President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024